Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Beth M Beadle, Annie W Chan
No abstract text is available yet for this article.
June 1, 2023: JAMA Oncology
#2
JOURNAL ARTICLE
David E Gerber, Elizabeth K S Barksdale
No abstract text is available yet for this article.
June 1, 2023: JAMA Oncology
#3
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 1, 2023: JAMA Oncology
#4
JOURNAL ARTICLE
Michael Hoerger, James Gerhart, Maria C Swartz
No abstract text is available yet for this article.
June 1, 2023: JAMA Oncology
#5
JOURNAL ARTICLE
Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, Antoine Berger, Xavier Liem, Sébastien Guihard, Sophie Chapet, Sébastien Thureau, Pierre Auberdiac, Pascal Pommier, Amandine Ruffier, Lionel Perrier, Anne Devillers, Boris Campillo-Gimenez, Renaud de Crevoisier
IMPORTANCE: Xerostomia is a major toxic effect associated with intensity-modulated radiotherapy (IMRT) for oropharyngeal cancers. OBJECTIVE: To assess whether adaptive radiotherapy (ART) improves salivary function compared with IMRT in patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomized clinical trial was conducted in 11 French centers. Patients aged 18 to 75 years with stage III-IVB squamous cell oropharyngeal cancer treated with chemoradiotherapy were enrolled between July 5, 2013, and October 1, 2018...
June 1, 2023: JAMA Oncology
#6
JOURNAL ARTICLE
Lili Mao, Bin Lian, Caili Li, Xue Bai, Li Zhou, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Xuan Wang, Bixia Tang, Xieqiao Yan, Siming Li, Yan Kong, Jie Dai, Xiaoting Wei, Juan Li, Rong Duan, Huayan Xu, Xiaowen Wu, Yue Yang, Fengzhuo Cheng, Cheng Zhang, Fangzhou Xia, Zheng Pang, Jun Guo, Lu Si
IMPORTANCE: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking. OBJECTIVE: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma. DESIGN, SETTING, AND PARTICIPANTS: In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021...
June 1, 2023: JAMA Oncology
#7
JOURNAL ARTICLE
Alyson Haslam, Vinay Prasad
No abstract text is available yet for this article.
June 1, 2023: JAMA Oncology
#8
JOURNAL ARTICLE
Luca Borah, Megan Lane, Hari Nathan
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#9
JOURNAL ARTICLE
Nancy U Lin
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#10
JOURNAL ARTICLE
Malgorzata K Nowakowska, Rachel M Ortega, Mackenzie R Wehner, Kevin T Nead
IMPORTANCE: The use of second-generation antiandrogens (AAs) in the treatment of prostate cancer is increasing. Retrospective evidence suggests an association between second-generation AAs and adverse cognitive and functional outcomes, but further data from prospective trials are needed. OBJECTIVE: To examine whether evidence from randomized clinical trials (RCTs) in prostate cancer supports an association between second-generation AAs and cognitive or functional toxic effects...
May 25, 2023: JAMA Oncology
#11
JOURNAL ARTICLE
Robert W Holloway, Alberto A Mendivil, James E Kendrick, Lisa N Abaid, John V Brown, Jane LeBlanc, Nathalie D McKenzie, Kristina M Mori, Sarfraz Ahmad
IMPORTANCE: Patients with platinum-resistant or platinum-refractory ovarian cancer (PRROC) have limited therapeutic options, representing a considerable unmet medical need. OBJECTIVE: To assess antitumor activity and safety of intraperitoneal (IP) olvimulogene nanivacirepvec (Olvi-Vec) virotherapy and platinum-based chemotherapy with or without bevacizumab in patients with PRROC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, nonrandomized multisite phase 2 VIRO-15 clinical trial enrolled patients with PRROC with disease progression following their last prior line of therapy from September 2016 to September 2019...
May 25, 2023: JAMA Oncology
#12
JOURNAL ARTICLE
Alexandra O Sokolova, Julie N Graff
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#13
JOURNAL ARTICLE
Erica S Tsang, Pamela N Munster
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#14
JOURNAL ARTICLE
Muhammad Hamza Shah
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#15
JOURNAL ARTICLE
Dun-Chang Mo, Peng-Hui Luo, Jian-Feng Huang
No abstract text is available yet for this article.
May 25, 2023: JAMA Oncology
#16
JOURNAL ARTICLE
Kelli B Pointer, Na Tosha N Gatson
No abstract text is available yet for this article.
May 18, 2023: JAMA Oncology
#17
JOURNAL ARTICLE
Rifaquat Rahman, Steffen Ventz, Lorenzo Trippa
No abstract text is available yet for this article.
May 18, 2023: JAMA Oncology
#18
JOURNAL ARTICLE
Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troiani
IMPORTANCE: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. OBJECTIVE: To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from June 2019 to April 2022...
May 18, 2023: JAMA Oncology
#19
JOURNAL ARTICLE
Connor J Kinslow, Ann Mercurio, Prashanth Kumar, Ali I Rae, Markus D Siegelin, Jack Grinband, Kekoa Taparra, Pavan S Upadhyayula, Guy M McKhann, Michael B Sisti, Jeffrey N Bruce, Peter D Canoll, Fabio M Iwamoto, Lisa A Kachnic, James B Yu, Simon K Cheng, Tony J C Wang
IMPORTANCE: O6-methylguanine-DNA methyltransferase (MGMT [OMIM 156569]) promoter methylation (mMGMT) is predictive of response to alkylating chemotherapy for glioblastomas and is routinely used to guide treatment decisions. However, the utility of MGMT promoter status for low-grade and anaplastic gliomas remains unclear due to molecular heterogeneity and the lack of sufficiently large data sets. OBJECTIVE: To evaluate the association of mMGMT for low-grade and anaplastic gliomas with chemotherapy response...
May 18, 2023: JAMA Oncology
#20
JOURNAL ARTICLE
Jacob J Mandel, John F de Groot
No abstract text is available yet for this article.
May 18, 2023: JAMA Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
